Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1991 1
1992 2
1993 2
1994 2
1995 6
1996 6
1997 10
1998 14
1999 10
2000 5
2001 3
2002 4
2003 7
2004 7
2005 2
2006 8
2007 8
2008 12
2009 8
2010 9
2011 6
2012 1
2013 4
2014 7
2015 6
2016 6
2017 9
2018 11
2019 10
2020 4
2021 8
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

183 results
Results by year
Filters applied: . Clear all
Page 1
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
Bureau C, Thabut D, Jezequel C, Archambeaud I, D'Alteroche L, Dharancy S, Borentain P, Oberti F, Plessier A, De Ledinghen V, Ganne-Carrié N, Carbonell N, Rousseau V, Sommet A, Péron JM, Vinel JP. Bureau C, et al. Among authors: oberti f. Ann Intern Med. 2021 May;174(5):633-640. doi: 10.7326/M20-0202. Epub 2021 Feb 2. Ann Intern Med. 2021. PMID: 33524293 Clinical Trial.
Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, Mathurin P, Otal P, Cabarrou P, Péron JM, Vinel JP. Bureau C, et al. Among authors: oberti f. Gastroenterology. 2017 Jan;152(1):157-163. doi: 10.1053/j.gastro.2016.09.016. Epub 2016 Sep 20. Gastroenterology. 2017. PMID: 27663604 Free article. Clinical Trial.
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. Vilgrain V, et al. Among authors: oberti f. Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107679 Clinical Trial.
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P, Diehl AM. Boursier J, et al. Among authors: oberti f. Hepatology. 2016 Mar;63(3):764-75. doi: 10.1002/hep.28356. Epub 2016 Jan 13. Hepatology. 2016. PMID: 26600078 Free PMC article.
Thabut D, Weil D, Bouzbib C, Rudler M, Cassinotto C, Castéra L, Serste T, Oberti F, Ganne-Carrié N, de Lédinghen V, Bourlière M, Bureau C. Thabut D, et al. Among authors: oberti f. Clin Res Hepatol Gastroenterol. 2021 Jul 28:101767. doi: 10.1016/j.clinre.2021.101767. Online ahead of print. Clin Res Hepatol Gastroenterol. 2021. PMID: 34332128
The epidemiology of Budd-Chiari syndrome in France.
Ollivier-Hourmand I, Allaire M, Goutte N, Morello R, Chagneau-Derrode C, Goria O, Dumortier J, Cervoni JP, Dharancy S, Ganne-Carrié N, Bureau C, Carbonell N, Abergel A, Nousbaum JB, Anty R, Barraud H, Ripault MP, De Ledinghen V, Minello A, Oberti F, Radenne S, Bendersky N, Farges O, Archambeaud I, Guillygomarc'h A, Ecochard M, Ozenne V, Hilleret MN, Nguyen-Khac E, Dauvois B, Perarnau JM, Lefilliatre P, Raabe JJ, Doffoel M, Becquart JP, Saillard E, Valla D, Dao T, Plessier A; French Network for Vascular Disorders of the Liver. Ollivier-Hourmand I, et al. Among authors: oberti f. Dig Liver Dis. 2018 Sep;50(9):931-937. doi: 10.1016/j.dld.2018.04.004. Epub 2018 Apr 12. Dig Liver Dis. 2018. PMID: 29803757
183 results